

# INTERIM DATA ON DUAL INHIBITION OF POST- RADIOGENIC ANGIO-VASCULOGENESIS BY OLAPTESED PEGOL (NOX-A12) AND BEVACIZUMAB IN GLIOBLASTOMA FROM THE FIRST EXPANSION ARM OF THE PHASE 1/2 GLORIA TRIAL Frank A. Giordano<sup>1,2</sup>, Julian P. Layer<sup>3,4</sup>, Sonia Leonardelli<sup>4</sup>, Lea L. Friker<sup>4,5</sup>, Christina Schaub<sup>6</sup>, Thomas Zeyen<sup>6</sup>, Elena Sperk<sup>1,7</sup>, Peter Hambsch<sup>8</sup>, Christoph Oster<sup>9</sup>, Franziska Grau<sup>3,10</sup>,

<sup>1</sup> Department of Radiation Oncology, University Medical Center Mannheim; <sup>3</sup> Department of Radiation Oncology, University Hospital Bonn, University of Bonn; <sup>4</sup> Institute of Experimental Oncology, University Hospital Bonn, University of Bonn; <sup>5</sup> Institute of Neurology, University Hospital Bonn; <sup>7</sup> Clinical Trials Unit, University Medical Center Mannheim, University of Heidelberg; <sup>8</sup> Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen; <sup>10</sup> Department of Radiation Oncology, University Hospital Bonn, University of Bonn; <sup>11</sup> Institute of Neurology, University Hospital Leipzig; <sup>12</sup> Department of Neurology, University of Tübingen; <sup>14</sup> Lysholm Department of Neuroradiology, University Hospital Tübingen; <sup>14</sup> Lysholm Department of Neurology, <sup>14</sup> Lysholm Department National Hospital for Neurology and Neurosurgery, London; <sup>15</sup> Department of Neurosurgery, University Hospital Leipzig, University of Leipzig

UNIVERSITÄT LEIPZIG





Daniel Paech<sup>10</sup>, Wolf Müller<sup>11</sup>, Torsten Pietsch<sup>5</sup>, L. Christopher Schmeel<sup>3</sup>, Oliver Grauer<sup>12</sup>, Mirjam Renovanz<sup>13</sup>, Ghazaleh Tabatabai<sup>13</sup>, Sied Kebir<sup>10</sup>, Sotirios Bisdas<sup>14</sup>, Erdem Güresir<sup>15</sup>, Martin Glas<sup>10</sup>, Clemens Seidel<sup>11</sup>, Michael Hölzel<sup>4</sup> and Ulrich Herrlinger<sup>6</sup>

Trial sponsored by TME Pharma AG.

Registered with clinicaltrials.gov, ID: NCT04121455, and EudraCT 2018-004064-62

